Bellevue Group AG increased its position in shares of Intercept Pharmaceuticals (NASDAQ:ICPT) by 64.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 31,900 shares of the biopharmaceutical company’s stock after acquiring an additional 12,500 shares during the period. Bellevue Group AG owned approximately 0.11% of Intercept Pharmaceuticals worth $1,962,000 at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. Peregrine Capital Management LLC acquired a new position in Intercept Pharmaceuticals during the fourth quarter worth about $7,055,000. Hudson Bay Capital Management LP acquired a new position in Intercept Pharmaceuticals during the fourth quarter worth about $1,753,000. Raymond James & Associates acquired a new position in Intercept Pharmaceuticals during the fourth quarter worth about $1,991,000. Amalgamated Bank purchased a new position in Intercept Pharmaceuticals in the 4th quarter worth about $209,000. Finally, State of Wisconsin Investment Board increased its stake in Intercept Pharmaceuticals by 221.0% in the 4th quarter. State of Wisconsin Investment Board now owns 11,689 shares of the biopharmaceutical company’s stock worth $683,000 after purchasing an additional 8,047 shares in the last quarter. 66.19% of the stock is currently owned by hedge funds and other institutional investors.
A number of brokerages recently weighed in on ICPT. ValuEngine cut Intercept Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Goldman Sachs cut Intercept Pharmaceuticals from a “neutral” rating to a “sell” rating in a research note on Wednesday, February 7th. Wedbush reissued a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Friday. BidaskClub raised Intercept Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, January 25th. Finally, Zacks Investment Research raised Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, February 19th. Four analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have issued a buy rating to the company. The company has an average rating of “Hold” and an average price target of $125.05.
Shares of Intercept Pharmaceuticals opened at $70.12 on Tuesday, according to Marketbeat Ratings. Intercept Pharmaceuticals has a one year low of $51.05 and a one year high of $135.59. The stock has a market cap of $2.14 billion, a price-to-earnings ratio of -4.88 and a beta of -1.80. The company has a debt-to-equity ratio of -6.88, a current ratio of 4.58 and a quick ratio of 4.58.
Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings data on Tuesday, May 8th. The biopharmaceutical company reported ($3.22) EPS for the quarter, topping the Zacks’ consensus estimate of ($3.41) by $0.19. Intercept Pharmaceuticals had a negative return on equity of 573.64% and a negative net margin of 241.33%. The firm had revenue of $35.96 million during the quarter, compared to analyst estimates of $38.44 million. During the same period last year, the company posted ($3.61) EPS. The business’s quarterly revenue was up 70.9% compared to the same quarter last year. equities analysts expect that Intercept Pharmaceuticals will post -11.66 EPS for the current year.
In other news, CEO Mark Pruzanski purchased 7,812 shares of Intercept Pharmaceuticals stock in a transaction dated Monday, April 9th. The stock was acquired at an average cost of $64.00 per share, for a total transaction of $499,968.00. Following the acquisition, the chief executive officer now directly owns 11,642 shares in the company, valued at $745,088. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Keith Michael Gottesdiener purchased 1,171 shares of Intercept Pharmaceuticals stock in a transaction dated Monday, April 9th. The shares were purchased at an average price of $64.00 per share, with a total value of $74,944.00. Following the completion of the acquisition, the director now owns 5,001 shares in the company, valued at $320,064. The disclosure for this purchase can be found here. Insiders have acquired a total of 399,608 shares of company stock valued at $25,574,912 over the last 90 days. Corporate insiders own 4.90% of the company’s stock.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).
Want to see what other hedge funds are holding ICPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intercept Pharmaceuticals (NASDAQ:ICPT).
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.